SDC1 and Miyoshi myopathy: In this context, the evaluation of CD138+ miR-25 levels significantly improved the risk-stratification of MM patients, resulting in the advanced positive prediction of patients’ poor treatment outcome within R-ISS II, high-risk cytogenetics and optimal treatment responders (sCR, CR, VGPR) subgroups.